Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 18/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27211643 | 1.00 | DGAT2 (0.73) | DGAT2KMT2AATM | |
| SCHEMBL27211623 | 1.00 | DGAT2 (0.73) | DGAT2KMT2AATM | |
| SCHEMBL25352205 | 0.94 | DGAT2 (0.64) | DGAT2KMT2AATM | |
| SCHEMBL25352504 | 0.92 | DGAT2 (0.77) | DGAT2KMT2AATM | |
| SCHEMBL29511902 | 0.92 | DGAT2 (0.77) | DGAT2KMT2AATM | |
| SCHEMBL29061636 | 0.89 | DGAT2 (0.76) | DGAT2KMT2AATM | |
| SCHEMBL29512127 | 0.88 | DGAT2 (0.76) | DGAT2KMT2AATM | |
| SCHEMBL27211604 | 0.88 | DGAT2 (0.76) | DGAT2KMT2AATM | |
| SCHEMBL25349605 | 0.87 | DGAT2 (0.80) | DGAT2KMT2AATM | |
| SCHEMBL29511941 | 0.87 | DGAT2 (0.80) | DGAT2KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | claimed |
| CN-116685577-A | Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-01 | — | — | CN | claimed |
| EP-4225739-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2022076495-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | claimed |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | claimed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | Merck Sharp & Dohme, LLC (US) | 2024-05-07 | — | — | US | disclosed |
| CN-116685577-A | Preparation of benzimidazolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4225739-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076495-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112182-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | DGAT2 1/4885KMT2A 644/4885ATM 2159/4885 |
| US-11976061-B2 | Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | DGAT2 1/4885KMT2A 644/4885ATM 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.